Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060567 · ClinicalTrials.gov registry record · Phase 1
Dose-Finding Study of E7070 in Combination With Irinotecan
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT00060567 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 88 participants.
The verdict
NCT00060567, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.
Interventions
- DRUG E7070 + irinotecan combination
- DRUG Irinotecan + E7070 combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2003-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060567
The ClinicalTrials.gov registry entry for NCT00060567 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which E7070 + irinotecan combination is the first listed.
NCT00060567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060567 about?
NCT00060567 is a clinical study titled "Dose-Finding Study of E7070 in Combination With Irinotecan". E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.
What is the current status of trial NCT00060567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2003-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00060567?
The interventions under investigation include: E7070 + irinotecan combination (DRUG), Irinotecan + E7070 combination (DRUG).
Who is sponsoring clinical trial NCT00060567?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.